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ABSTRACT
Objective: To identify abnormal levels of urine metabolites and cells that serve as 
markers of existing kidney disorders in ambulatory HIV-infected patients.
Design: A cross sectional study. 
Setting: Nyanza Provincial General Hospital’s patient support centre. 
Subjects: A total of 593 HIV infected patients were studied.
Intervention: Dipstick urinalysis test was used to screen mid stream urine to detect 
constituents with altered levels.
Results: Out of the 593 participants, the urine of 214 (36.1%) had abnormally altered 
levels of urine constituents, with more females afflicted than males [41.5% vs. 27.8%; 
OR 1.84 (1.28-2.63), χ2= 11.08, p=0.0009]. Urobilinogen was the most common urine 
metabolite while ketones were least commonly present. More participants had altered 
levels of leucocytes than erythrocytes in urine. Patients with pyuria were three times 
more likely to have elevated erythrocytes in their urine as well ( χ2= 34.37, p<0.0001). 
Similarly, the risk of having proteinuria was three times higher in patients with 
pyuria (p<0.0003, Fisher’s test). Patients with erythrocytes in urine also had a threefold 
likelihood of having proteinuria (P<0.0003, Fisher’s test). Fewer ARV users had abnormal 
urine markers [15.7% vs 24.3% OR 0.62 (0.41-0.94), χ2= 5.2, p<0.05]. 
Conclusion: Metabolites and cellular markers of kidney disorders were prevalent in 
the urine of HIV patients especially females and those with pronounced immune 
depletion (CD4 counts equal to or below 500). ARVs use was associated with reduced 
manifestation of these markers. 
INTRODUCTION
Kidney complications are fast surpassing opportunistic 
infections as causes of morbidity and mortality in 
HIV patients in the post highly active anti-retroviral 
(HAART) drugs era (1). However, the prevalence 
of kidney disorders among HIV patients has been 
difficult to estimate due to the diverse spectrum of 
renal disorders encountered in this population and 
lack of standardised recognition and appropriate 
reporting mechanism (2). Gerntholtz and colleagues 
(3) in a South African study reported that 27% of 
the renal biopsies showed HIV associated kidney 
disease. 
 Kidney damage can be induced by diseases 
intrinsic or extrinsic to the kidneys. Damaged 
kidneys cannot regulate appropriately the amounts 
of electrolytes, metabolites and cells excreted through 
it. Subsequently, the levels of these constituents in 
urine are gradually altered. In HIV patients, kidney 
disease has been attributed to direct infection and 
indirect damage of kidney cells by the virus and to 
toxic damage induced by anti-retroviral drugs (ARVs) 
(4). Szczech et al (5) reported that the HIV virus 
induces histological damage to the kidney glomeruli, 
tubules and interstitium. Generally, damage to the 
kidney parenchyma can lead to excessive excretion 
of metabolites, electrolytes and cellular elements in 
urine (6). The metabolites, electrolytes or cellular 
elements present in abnormal levels in urine are 
therefore at times typical of the particular underlying 
damage to the kidney (7). Haematuria accompanied 
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by persistent proteinuria iscommon manifestation of 
underlying glomerulardisease (8), while leukocyturia 
is commonly indicative of urinary tract infection 
(9). Various tests can assess the presence of these 
constituents in urine including the dipstick urinalysis 
test which was employed in the current study (10).
The most common HIV related kidney disease is HIV 
associated nephropathy (HIVAN). Studies in USA and 
Europe have demonstrated that HIVAN has a higher 
prevalence among patients of African descent (11). 
An estimated 85-97% of HIVAN patients are black 
African or Afro- Caribbean (12). The risk factors for 
HIV associated kidney disease have therefore been 
suggested to be more in the black race and lower 
CD4 lymphocyte cells count (5).  It is unknown why 
patients of black African descent predominantly 
suffer HIV induced pathology. In the USA therefore, 
it has been recommended that all patients with newly 
diagnosed HIV infection should be screened for the 
presence of chronic kidney disease (4).
 In Africa, despite having a higher population 
of HIV infected people at over 25 million, adequate 
information is not available concerning HIV 
associated renal diseases (13). It has therefore not 
been established whether the prevalence of HIVAN 
among indigenous black African patients mirrors that 
of HIV-1 infected black patients in the United States. 
Wools-Kaloustian et al (14) found that the prevalence 
of renal dysfunction ranged between 1-15% in a cross 
sectional study of 373 HIV patients in western Kenya. 
Han et al (15) evaluated 615 HIV patients in South 
Africa and reported that 6% had overt proteinuria 
while 36% showed micro albuminuria. A cross 
sectional survey of HAART naïve Ugandans by Olson 
et al (16) revealed that 21% had dipstick proteinuria. 
In a study of a cohort of HAART naïve Rwandan 
women, it was established that the prevalence of 
proteinuria was 13% (17).
 Despite the fact that HIV related nephropathies 
rapidly progresses to end stage renal disease (ESRD) 
and death, kidney disease has not received as 
much attention as the opportunistic infections and 
malignancies that contribute to AIDS (18). Even 
though it has been observed that highly active anti-
retroviral therapy has heralded improved survival, 
kidney, liver and cardiac diseases have become 
increasingly important sources of mortality and 
morbidity in patients with HIV (2). Vigilant attention 
to the kidneys and renal function is therefore necessary 
for optimal care of HIV patients (19). Assessment of 
kidney function and recognition of acute or chronic 
kidney disease is also essential for appropriate dose 
modification in HIV-infected patients exposed to 
complex medication regimens in the HAART era. As 
such, attention needs to be focused on early detection, 
prevention and control of kidney diseases in this 
group.
 Cho et al (20) recommended routine urinalysis 
in HIV patients and especially for patients receiving 
potentially nephrotoxic drugs or exhibiting signs of 
kidney disease such as oedema and hypertension. 
They noted that urinalysis is an excellent screening 
test for providing clues concerning the three cardinal 
manifestations of kidney disease namely haematuria, 
proteinuria and pyuria. This study was therefore 
designed to investigate the frequency of presentation 
of markers of kidney dysfunction in urine in HIV 
patients attending the patient support centre in 
Nyanza Provincial General Hospital in Kisumu, 
Kenya.
MATERIALS AND METHODS
This study was carried out at the Nyanza provincial 
hospital’s patient support center in Kisumu 
municipalityof Kisumu county, western Kenya. 
The most prevalent diseases in Kisumu county are 
malaria, anemia and HIV/AIDS; HIV prevalence 
is about 14.9% and is the highest in the country 
(21). This was a cross sectional and the participants 
enrolled were above 18 years, HIV-infected, able 
and willing to provide consent. Ethical review and 
approval was done by the provincial hospital’s 
research committee.
 Five hundred and ninety three participants 
were enrolled in the study out of the nine hundred 
and fifty (950) clients from beginning of September 
to the end of October 2009. After administering the 
requisite information in the consent forms and routine 
medical history and examination, volunteers were 
requested to donate five mls of midstream urine for 
screening. 
 The urine samples were tested immediately using 
urinalysis strips to assess the presence of abnormally 
raised concentrations of electrolyte, metabolites and 
cellular entities of interest. The strips were dipped in 
the urine briefly and withdrawn. The observed colour 
changes in the segments of the strips were compared 
to a colour chart to obtain results, which were entered 
in a proforma designed specifically for the study. The 
urinalysis strips used were Uriscan 10 SGL strips 
(Diagnostics, Korea) for assessing the presence of 
eight parameters associated with kidney disorders. 
These parameters included proteins, white blood cells 
(leukocytes), glucose, bilirubin, urobilinogen, nitrites, 
red blood cells (erythrocytes), and ketones. The dip 
stick screen is a qualitative and semi-quantitave 
assessment tool which by use of graded colour charts, 
detects the variations of concentrations of specified 
urine constituents. Information concerning the HIV 
profile of the patients such as CD4 cell levels and ARVs 
used as well as demographic data were abstracted 
from the most recent reports contained in the patient’s 
hospital records. 
497 East african MEdical Journal December 2010 
 The study did not assess the magnitude of 
reduction of kidney functional efficiency and the 
actual underlying kidney pathology. It did not 
quantify the actual levels of individual markers 
present in the urine samples, and function specific 
tests such as 24 hour glomerular filtration rate and 
creatinine clearance were not done.
 Data were entered in Microsoft Excel spreadsheet 
(Microsoft Corporation) and analysed using SPSS 
(Version 10.0) and R computer programmes for 
basic descriptive and inferential statistics. The 
dependent variables included the eight parameters; 
proteins, leucocytes, glucose, nitrites, urobilinogen, 
bilirubin, erythrocytes, and ketones. To analyse 
these parameters, age, gender, ARV use, and CD4 
cell count served as the independent variables. To 
determine the relationship between the dependent 
and independent variables, a Chi-square test or a 
Fisher’s exact test was used with p<0.05 considered 
statistically significant.
RESULTS
Table 1 shows the characteristics of the study 
population. Out of the 593 participants, 366 (61.7%) 
were females while 227 (38.3%) were males. The 
mean age of the participants was 37.7 years with 
50% falling between 31 and 44 years. The majority 
of participants (69.1%) had CD4 cell count equal 
to or below 500 cells per microliter and their mean 
CD4 count was 412.7 cells per microliter of blood. A 
large majority of the patients (80.4%) screened were 
undergoing anti-retroviral treatment.
Table 1 




CD4 > 500  29.7
CD4 ≤ 500  69.1
ARV users  80.4
No ARVs  19.6
Key: ARVs- Anti-retroviral drugs: CD4- CD4 
lymphocytes
 Table 2 shows the frequency of samples that tested 
positive for abnormally raised levels of individual 
markers of altered kidney health in the entire study 
population. At least one marker was detected in urine 
samples of 214 (36.1%) participants. The most common 
constituents detected were leucocytes in 17.5% (95% 
C.I. 14.5-20.6%) of participants, erythrocytes 15% (95% 
C.I. 12.1-17.9%), and urobilinogen 10.1% (95% C.I. 
8-12.9%). The least common markers were ketones 
and glucose.
 Analysis of the association of gender, CD4 
lymphocyte levels and anti-retroviral drugs with 
presence of markers in urine revealed that only gender 
and antiretroviral drugs usage were significantly 
associated with the occurrence of abnormal markers 
in urine (Table 3).  A higher proportion of female 
participants had with markers of kidney disorders 
in their urine samples compared to male participants 
[OR 1.84 (1.28-2.63), χ2= 11.08 p=0.0009]. This disparity 
occurred in gender at all the levels of CD4 lymphocyte 
immune cells depletion. Females with CD4 count 
above 500 cells/µL had significantly higher markers 
than males with CD4 count above 500 [OR 3.80 (1.58-
9.14), χ2= 9.7, p=0.002]. Similarly at CD4 cell count 
equal to or below 500, females had more markers 
than males [OR 1.59 (1.06-2.40), χ2= 4.99, p=0.02]. 
Among the male participants, those with progressive 
immune depletion (CD4 count below 500) were more 
likely to have markers of kidney disorders in their 
urine than those with more robust immunity (CD4 
count above 500) [OR  2.6885 (1.137-6.3644), χ2= 5.4, 
p=0.02]. Among female patients only, there were no 
significant variations in marker occurrence across 
immunity levels as observed in male patients.
 ARV use was associated with a reduction in 
the prevalence of markers while non usage of ARVs 
was associated with increase of the markers [OR 0.62 
(0.41-0.94),χ2= 5.2, p=0.02] (Table 3). The reduction of 
markers associated with ARV use was more prominent 
in males compared to females [OR 0.55 (0.37-0.82),χ2= 
8.7, p=0.003]. This impact of medication was more 
pronounced at CD4 count below 500, where ARV 
use led to more reduction in prevalence of markers 
in males than in females. However at CD4 cell levels 
above 500, ARV use was not associated with significant 
difference in prevalence of markers among male and 
female patients. Within each gender, apart from males 
with CD4 cell levels below 500, ARV use was not 
associated with significant changes in the proportions 
of individuals depicting these markers. Males with 
CD4 count below 500 undergoing ARV treatment 
however had less markers than those not on ARVs 
[OR 0.3273 (0.14-0.765),  χ2 = 7.1, p=0.008)] with the 
same level of CD4 lymphocyte count (Table 3).
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Table 3
Chi-square (χ2) analysis of the distribution of urine markers of kidney disorders among gender, ARV use and CD4 
counts in the HIV population.
Patient profile Markers present Markers absent χ2   p-value
Females  151    215  11.08   0.0009
Males 63 164  
ARV yes 161 315 5.22 0.0223
ARV no 52 63  
CD4>500 58 118 0.25
CD4≤500 154 256  
Males ARV yes 49 140 8.73 0.0031
Females ARV yes 112 175  
Males CD4>500 7 41  5.36   0.0206
Females CD4>500 50 77 9.74 0.0018
Males CD4<500 56 122  
Females CD4<500 98 134 4.99 0.0255
Males ARV yes 42 110 7.71 0.0055
CD4<500
Females ARV yes 80 110 
CD4<500  
Males CD4<500,  42 110 7.08 0.0078
ARV yes
Males CD4<500 14  12 
ARV no   
Key: CD4≤500- CD4 cell count equal to or less than 500/µL: CD4>500- CD4 cell count more than 
500/µL: ARV no- not on anti-retroviral drugs; ARV yes-using anti-retroviral drugs.
 The prevalence of occurrence of individual 
markers such as leukocytes, erythrocytes and 
urobilinogen significantly varied between gender 
and ARV use and they tended to be less in males 
and ARV users and higher in females and ARV non 
users. The proportion of females with leucocytes in 
urine was significantly higher than that of males [OR 
3.57 (2.08-6.12), χ2= 2.5, p<0.0001] (Table 4). Similarly, 
females with erythrocytes in urine were significantly 
more than males with erythrocytes in urine [OR 1.71 
(1.04-2.81), χ2 = 4.6, p=0.03] (Table 5). The prevalence 
of leucocytes among participants not using ARVs was 
significantly higher than those using ARVs detected 
with leucocytes in urine [OR 1.73 (1.05-2.82), χ2=4.8, 
p=0.03] (Table 4). Similarly, urobilinogen was detected 
more frequently in ARV users than in ARV non users 
[OR 0.55 (0.30-0.98), χ2=4.1, p=0.04] (Table 6). 
Table 2
Frequency of urine markers for the entire study population (n=593)
 Urine markers
 Erythrocytes Ketones Glucose Protein Bilirubin Urobilinogen  Leucocytes  Nitrate
Negative 504 591 589 561  579 531 489 581
Positive 89 2 4 32 14 62 104 11
Prevalence 15% 0.3% 0.7% 5.4% 2.4% 10.5% 17.5% 1.9%
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Table 4 
Association of gender and ARV use with leucocytes in urine.
Patient Leucocyte present Leucocytes absent OR   χ2 P-value
On ARV 75 402 1.73 4.8 0.03
Not on ARV 28 87   
Males 18 209 3.57 2.5 <0.0001
Females 86   280   
Table 5
Association of gender with erythrocytes in urine
Gender  Erythrocytes Erythrocytes Total
 present  absent
Males  25 202 227
Females 64 302 366
Total 89 504 593
OR 1.71, χ2= 4.6, p=0.03
Table 6
Association of ARV use with urobilinogen in urine
ARV use Urobilinogen Urobilinogen Total
 present absent
On ARV 44 433 477
Not on ARV 18 97 115
Total 62 530 592
OR 0.55, χ2=4.1, p=0.04
 Among routinely clinically assessed markers 
of kidney disorders in urine (leucocytes, glucose, 
erythrocytes and proteins), leucocytes tended to be 
more common, followed by erythrocytes, proteins and 
glucose in descending order. Patients presenting with 
leucocytes, erythrocytes or protein were also found to 
be more likely to have other markers of kidney disor-
ders in their urine. Having leucocytes, predisposed 
one to three times the risk of having erythrocytes 
in urine as well, compared to patients without leu-
cocytes in urine (RR=3.047; =34.37,p<0.0001) (Table 
7). Similarly, having leucocytes elevated the risk of 
having protein in urine threefold compared to those 
deficient of leucocytes in urine (RR= 3.657; p<0.0003 
by Fisher’s test). The risk of having protein in urine 
was four times higher in patients with erythrocytes 
in urine than in patients without erythrocytesin urine 
(RR=3.874; p<0.0003 by Fisher’s test) (Table 8).
Table 8 
Comparison of risk of having protein in individuals 
with erythrocyte in urine 
Patient Protein Protein Total
 present absent
Erythrocytes 
present 13 76 89
Erythrocytes 
absent 19 485 504
Total 32 561 593
Risk ratio=3.8746; p<0.0002
Table 7
Comparison of risk of having erythrocytes and protein in urine in individuals with leucocytes and without 
leucocytes in urine.
Patient Leukocytes present  Leukocytes absent RR χ2      P-value
Erythrocytes present in urine 35 54 3.0475  34.37     <0.0001
Erythrocytes absent in urine 69 435   
Protein present in urine 14 18 3.6571 16.07     <0.0001
Protein absent in urine 90 471   
RR – Risk ratio
DISCUSSIONS
The results of this study have shown that markers 
associated with kidney disorders are not common in 
HIV patients in western Kenya. All the tested markers 
were found to be present in abnormally raised levels 
in the urine of some of the participants. Indicators of 
deranged kidney health and functions were observed 
in urine samples of 36.1% of the patients assessed. In 
Kenya, a study by Wools-Kaloustian et al (14)noted 
that the prevalence of HIV related renal impairment 
was 11.5%, while in Tanzania it was reported at 
28%. In Zambia, the prevalence was cited as 33.5% 
at baseline (22). Yet in South Africa it was reported 
500 East african MEdical Journal December 2010 
at 6%, Nigeria at 38% and Ivory Coast at 26% (23). 
Choi et al (24) cited the prevalence of chronic kidney 
disease in HIV patients as ranging from 3.5 to 32.6%. 
As such the prevalence established from the current 
study falls within the range of what has been described 
in other studies.
 Data from the current study has shown that 
female HIV patients and patients not on anti-retroviral 
drugs were identified with more markers of kidney 
dysfunction. Franey et al (25) found on the other 
hand that more male HIV patients had impaired 
kidney function. This difference could be attributed to 
investigative methodology employed or to prevailing 
health conditions that have skewed impact on gender 
health in the study setting. The current study observed 
that the prevalence of kidney disorders in males 
rises with progression of the disease especially in 
the absence of anti-retroviral treatment. However, 
it was also noted that males similarly showed more 
marked improvement of kidney health when put on 
anti-retroviral treatment.  Winston and Klotman (26) 
reported that treatment with anti-retroviral drugs 
reduced the risk of kidney disease in HIV patients 
by 40 to 60%.
 In this study, leukocytes, microscopic haematuria 
(erythrocytes), urobilinogen and proteins were the 
most common of the routinely screened constituents 
detected in the survey. Few studies have investigated 
risk factors associated with leukocyturia, haematuria 
and proteinuria among HIV patients. Proteinuria 
and haematuria indicate existence of structural 
damage of the kidney, while leukocyturia primarily 
indicate presence of active infection. Winston et al 
(27) identified uro-genital infection as a risk factor 
of acute kidney failure in HIV patients. In this study, 
leukocyturia was found in 17.5% of the population. 
However, patients not on anti-retroviral treatment 
had a higher prevalence of leukocyturia than 
those undergoing ARV treatment. Females had a 
higher prevalence of leukocyturia than males. This 
contrast between genders can be attributed to cyclic 
reproductive changes in female patients as much as 
to factors predisposing to ease of uro-genital infection 
in females. Fabian et al (23) reported 30% leukocyturia 
in routine urinary screening of patients attending 
anti-retroviral clinics in South Africa.  The finding 
of the this correlates only to leukocyturia levels 
reported in certain patient categories in previous 
studies. This further highlights the importance of 
patients’ characteristics and study methodology in 
determining the outcome of kidney complications in 
HIV patients. 
 This study observed microscopic haematuria in 
15% of the population investigated and significant 
prevalence differences were only noted between the 
genders. Females had higher haematuria than males. 
This could be attributed to pathological as well as 
physiological events within the female population. 
In males, CD4 lymphocyte levels and ARV use were 
associated with fluctuations in the numbers detected 
with haematuria while in females these factors were 
not associated with such changes. Having CD4 count 
above 500 cells/µL and using ARVs led to reduction 
generally in levels of microscopic hematuria in males. 
This was exemplified by males with CD4 count above 
500 and using ARVs who had only 2.8% afflicted with 
microscopic haematuria. On the contrary, males with 
CD4 count equal or below 500 and not using ARVs 
had 30.8% with haematuria. The reasons for these 
findings need to be established in future studies. 
Fabian and Neicker (23) reported that 33% of HIV 
infected outpatients in anti-retroviral clinics in South 
Africa had microscopic haematuria. This agrees with 
the prevalence reported in some of the categories 
from the current study. Patients with microscopic 
haematuria were more likely to be detected with 
leukocytes and proteins as well.
 Proteinuria is the most common manifestation 
of kidney damage and persistent proteinuria is the 
main marker for glomerular disease (28). Despite 
the high prevalence of kidney markers reported 
in this study, proteinuria was identified in only 
5.4% of the participants. This level of proteinuria 
prevalence remained almost constant in all categories 
of patients regardless of differences in gender, CD4 
levels and ARV use. These findings correspond 
with those of Han et al (15) and Wools-Kaloustian 
et al (14) who observed proteinuria in 6.2 and 6%, 
respectively, in separate studies. Cavalcante et al (28) 
similarly reported persistent proteinuria in 5.4% of 
their study population. They also noted that a low 
CD4 lymphocyte count (<200 cells per mm3) was 
significantly associated with proteinuria. However, 
the finding that proteinuria was detected in almost 
all categories of patients albeit in low prevalence, 
serve as a strong indication that a proportion of 
these patients experienced active kidney disorders. 
As such, further studies to investigate the utility of 
screening HIV patients for proteinuria as a cheap 
non-invasive means for assessing kidney health in 
our limited resource health settings may necessary.
 The finding in this study that markers associated 
with kidney disorders are prevalent in HIV patients in 
western region of Kenya calls for routine assessment 
of kidney complications in our health settings in 
order to mitigate early their negative impacts on 
the functions of this vital organ. Future studies need 
to focus on the risk factors associated with kidney 
complications in local HIV infected populations with 
special attention to gender variations.More studies 
are needed to design a standardised and appropriate 
methodology of investigating the multiple kidney 
disorders related to HIV infection. Histopathological 
studies would also greatly improve the understanding 
of pathogenesis of HIV related kidney disorders and 
their pathophysiology. This would help establish 
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features pathognomonic of kidney disorders and set 
a basis for defining a common investigative criterion 
for diagnosing and or monitoring kidney disorders 
in HIV patients.
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